Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVD 1208S-122
- Development stage
- Phase 1
- Lead developer
- Center for Vaccine Development and Global Health
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
**CVD 1208S-122** is an investigational, orally administered live-attenuated bacterial-vector vaccine developed at the University of Maryland, Baltimore to prevent infections caused by *Shigella flexneri* and enterotoxigenic *Escherichia coli*. It uses an attenuated *S. flexneri* 2a CVD 1208S backbone with deletions in *guaBA*, *set*, and *sen*, engineered to express ETEC colonization factor antigen I and heat-labile enterotoxin A2/B antigens. The single recombinant bacterial vaccine is intended to induce mucosal and systemic immune responses against both Shigella and ETEC; it was evaluated in a completed Phase 1 oral dose-escalation study in healthy adults. ([academic.oup.com](https://academic.oup.com/jid/article-abstract/234/1/9/8658755))
- Other names
- CVD 1208S-122 Shigella-ETEC VaccineCVD1208S-122 Shigella-ETEC VaccineCVD-1208S-122 Shigella-ETEC Vaccine
02
Targets
CfaE (Colonization factor antigen I minor subunit CfaE)LTA (Lymphotoxin-alpha)S. flexneri 2a LPS (Shigella flexneri serotype 2a lipopolysaccharide)
Beyond the preview
Go deeper on CVD 1208S-122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVD 1208S-122.